Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharmacol ; 860: 172537, 2019 Oct 05.
Article in English | MEDLINE | ID: mdl-31310751

ABSTRACT

The widely used db/db mouse as a model of diabetic nephropathy (DN) only mimics the early changes in human DN with a slow disease progression. Since high protein diet (HPD) has been reported to affect progression of nephropathy in both humans and mice, we investigated whether HPD could accelerate nephropathy in db/db mice. Diabetic (C57BLKS-Leprdb/db) and non-diabetic (C57BLKS-Leprdb/+) mice were fed either HPD (60 kcal% protein) or control diet (22 kcal% protein), from 7 to 22 weeks of age. In db/db mice, HPD was found to significantly increase all measured readouts of renal injury including albuminuria, renal hypertrophy, mesangial expansion and expression of a panel of DN related markers, including KIM-1, Ki67 and Collagen III, which increased on both gene and protein levels. Furthermore, HPD activated the Renin-angiotensin system significantly and increased hyperfiltration, measured as reduced plasma Cystatin C. Usefulness of the HPD db/db mouse as a model for faster drug efficacy studies was investigated in a 5-week treatment study with the SGLT2 inhibitor, dapagliflozin. Expectedly, dapagliflozin normalised blood glucose levels and improved glucose intolerance in both HPD and control diet mice. Only HPD db/db mice, not the control diet db/db mice, showed clear hyperfiltration that was significantly reduced with dapagliflozin treatment at both 2 and 4 weeks of treatment. In conclusion, these studies confirm that HPD can significantly accelerate progression of nephropathy in db/db mice, and that this model could be useful for rapid evaluation of drug targets with potential to ameliorate features of DN, especially glomerular hyperfiltration.


Subject(s)
Benzhydryl Compounds/pharmacology , Diabetic Nephropathies/chemically induced , Diabetic Nephropathies/drug therapy , Diet, High-Protein/adverse effects , Glucosides/pharmacology , Sodium-Glucose Transporter 2 Inhibitors/pharmacology , Sodium-Glucose Transporter 2/metabolism , Animals , Benzhydryl Compounds/therapeutic use , Biomarkers/blood , Blood Glucose/metabolism , Body Weight/drug effects , Diabetic Nephropathies/blood , Diabetic Nephropathies/physiopathology , Disease Progression , Gene Expression Regulation/drug effects , Glucosides/therapeutic use , Kidney/drug effects , Kidney/physiopathology , Mice , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL